116 related articles for article (PubMed ID: 34848451)
1. The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death.
Ruff JP; Kretz AL; Kornmann M; Henne-Bruns D; Lemke J; Traub B
Anticancer Res; 2021 Dec; 41(12):5973-5985. PubMed ID: 34848451
[TBL] [Abstract][Full Text] [Related]
2. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
3. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.
Lemke J; von Karstedt S; Abd El Hay M; Conti A; Arce F; Montinaro A; Papenfuss K; El-Bahrawy MA; Walczak H
Cell Death Differ; 2014 Mar; 21(3):491-502. PubMed ID: 24362439
[TBL] [Abstract][Full Text] [Related]
4. Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inhibitor, PH11.
Dao P; Smith N; Scott-Algara D; Garbay C; Herbeuval JP; Chen H
Cancer Lett; 2015 Apr; 360(1):48-59. PubMed ID: 25684663
[TBL] [Abstract][Full Text] [Related]
5. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
6. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
[TBL] [Abstract][Full Text] [Related]
7. Role of the eIF4E binding protein 4E-BP1 in regulation of the sensitivity of human pancreatic cancer cells to TRAIL and celastrol-induced apoptosis.
Chakravarthy R; Clemens MJ; Pirianov G; Perdios N; Mudan S; Cartwright JE; Elia A
Biol Cell; 2013 Sep; 105(9):414-29. PubMed ID: 23734772
[TBL] [Abstract][Full Text] [Related]
8. Glutamine-mediated epigenetic regulation of cFLIP underlies resistance to TRAIL in pancreatic cancer.
Kim JH; Lee J; Im SS; Kim B; Kim EY; Min HJ; Heo J; Chang EJ; Choi KC; Shin DM; Son J
Exp Mol Med; 2024 Apr; 56(4):1013-1026. PubMed ID: 38684915
[TBL] [Abstract][Full Text] [Related]
9. Chloroquine augments TRAIL-induced apoptosis and induces G2/M phase arrest in human pancreatic cancer cells.
Monma H; Iida Y; Moritani T; Okimoto T; Tanino R; Tajima Y; Harada M
PLoS One; 2018; 13(3):e0193990. PubMed ID: 29513749
[TBL] [Abstract][Full Text] [Related]
10. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
Radke DI; Ungefroren H; Helm O; Voigt S; Alp G; Braun H; Hübner S; Dilchert J; Sebens S; Adam D; Kalthoff H; Trauzold A
Cell Signal; 2016 Nov; 28(11):1652-62. PubMed ID: 27492861
[TBL] [Abstract][Full Text] [Related]
11. The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand.
Yang SZ; Xu F; Zhou T; Zhao X; McDonald JM; Chen Y
J Biol Chem; 2017 Jun; 292(25):10390-10397. PubMed ID: 28476883
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin.
Retzer-Lidl M; Schmid RM; Schneider G
Int J Cancer; 2007 Jul; 121(1):66-75. PubMed ID: 17304504
[TBL] [Abstract][Full Text] [Related]
13. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells.
Murtaza I; Saleem M; Adhami VM; Hafeez BB; Mukhtar H
Cancer Res; 2009 Feb; 69(3):1156-65. PubMed ID: 19176377
[TBL] [Abstract][Full Text] [Related]
14. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
Huang S; Sinicrope FA
Mol Cancer Ther; 2010 Mar; 9(3):742-50. PubMed ID: 20197401
[TBL] [Abstract][Full Text] [Related]
16. HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression.
Harashima N; Takenaga K; Akimoto M; Harada M
Oncotarget; 2017 Jun; 8(26):42887-42900. PubMed ID: 28476028
[TBL] [Abstract][Full Text] [Related]
17. Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL.
Adwan H; Murtaja A; Kadhim Al-Taee K; Pervaiz A; Hielscher T; Berger MR
Cancer Biol Ther; 2014 Sep; 15(9):1185-97. PubMed ID: 24918923
[TBL] [Abstract][Full Text] [Related]
18. Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway.
Chen Z; Sangwan V; Banerjee S; Chugh R; Dudeja V; Vickers SM; Saluja AK
Cancer Lett; 2014 Jun; 348(1-2):156-66. PubMed ID: 24662747
[TBL] [Abstract][Full Text] [Related]
19. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
20. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer.
Ozawa F; Friess H; Kleeff J; Xu ZW; Zimmermann A; Sheikh MS; Büchler MW
Cancer Lett; 2001 Feb; 163(1):71-81. PubMed ID: 11163110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
